JPY 610.0
(-0.65%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 100.4 Million JPY | 6.58% |
2022 | 94.2 Million JPY | 30.96% |
2021 | 71.93 Million JPY | 5.86% |
2020 | 67.94 Million JPY | -20.06% |
2019 | 85 Million JPY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 20 Million JPY | -30.35% |
2023 Q2 | 26.16 Million JPY | 5.59% |
2023 Q1 | 24.77 Million JPY | 0.99% |
2023 Q4 | 28.71 Million JPY | 38.41% |
2023 Q3 | 20.74 Million JPY | -20.69% |
2023 FY | 100.4 Million JPY | 6.58% |
2022 Q3 | 22 Million JPY | -0.56% |
2022 FY | 94.2 Million JPY | 30.96% |
2022 Q4 | 24.53 Million JPY | 11.51% |
2022 Q2 | 22.12 Million JPY | 0.0% |
2021 FY | 71.93 Million JPY | 5.86% |
2020 FY | 67.94 Million JPY | -20.06% |
2019 FY | 85 Million JPY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | 442.23 Billion JPY | 99.977% |
Astellas Pharma Inc. | 1603.67 Billion JPY | 99.994% |
Chugai Pharmaceutical Co., Ltd. | 1111.36 Billion JPY | 99.991% |
Ono Pharmaceutical Co., Ltd. | 502.67 Billion JPY | 99.98% |
Santen Pharmaceutical Co., Ltd. | 301.96 Billion JPY | 99.967% |
JCR Pharmaceuticals Co., Ltd. | 42.87 Billion JPY | 99.766% |
Daiichi Sankyo Company, Limited | 1601.68 Billion JPY | 99.994% |
Otsuka Holdings Co., Ltd. | 2018.56 Billion JPY | 99.995% |